

CURRICULUM VITAE

NAME: Anne-Marie **TABURET**

Born: September 21, 1951 in PARIS, FRANCE

Nationality: French

Phone: +33 684 201 444

Email: amtaburet@gmail.com, anne-marie.taburet@inserm.fr

Professional address:

Up to october 31, 2017 (retirement)

Clinical Pharmacy

Paris-Sud University Hospital BICETRE, Assistance Publique Hôpitaux de Paris

78 rue du Général Leclerc

94270 Le Kremlin Bicêtre - FRANCE

November 1st, 2017 up to March 2018

Consultant Pharmacist/pharmacologist (Research Associate)

UMR1184 INSERM/CEA/Paris-Sud University

From March 2018

pharmacologist advisor in the field of pharmacokinetic of antiinfectious drugs

EDUCATION/ TRAINING

- Pharmacist (Pharm D, Paris V-Paris Descartes University, 1973)
- Resident (Hospital clinical chemistry Laboratory, 1973-1977)
- Training:
 - experimental pharmacology, pharmacokinetics and therapeutic drug monitoring in Paris University
 - drug metabolism in Dr. GILLETTE Laboratory, (NIH - USA, 1977-1978), fellowship from Fondation pour l'Industrie Pharmaceutique, Paris
- Ph D Thesis in physiology and clinical pharmacokinetics (Pharmaceutical Faculty Paris XI-Paris Sud University, 1983)

POSITIONS and EMPLOYMENT

- Assistant Professor in Physiology from 1978 to 1986 (Faculty of Pharmacy, Chatenay-malabry, Paris-Sud University)
- Hospital Pharmacist since 1982:
 - Hospital Bicêtre (Assistance Publique Paris) in Dr SINGLAS Clinical Pharmacy Department.
 - Responsible of drug monitoring laboratory and clinical pharmacokinetic studies
- Position to retirement (1993-october 2017):
 - Head Clinical Pharmacy Department, Paris-Sud University Hospital Bicêtre (Assistance Publique - Paris, France)

SPECIAL FIELDS OF STUDY AND CLINICAL RESEARCH EXPERIENCE :

Clinical pharmacokinetics: therapeutic drug monitoring, drug metabolism, drug-drug interactions PK/PD relationships.

Special drugs of interest: immunosuppressive and antiinfectious drugs, antiviral drugs (HIV and HCV), and antituberculosis drugs

TEACHING

- Assistant professor in physiology 1978-1986 (Paris Sud University)
- Teaching clinical pharmacokinetics to pharmaceutical and medical students since 1985

- Teaching pharmacology of antiretroviral drugs to Cambodian physicians through ESTHER educational program
- Teaching pharmacokinetics at Institut Pasteur in the Clinical trials and infectious diseases lesson
- PhD supervisor (Paris-Sud University), 6 students (July 2008, December 2011-one student from Cambodia, June 2012, december 2013-from Rio de Janeiro University, for a student from Mozambique, cosupervisor for one Ugandan student from Montpellier University november 2015)

MEMBERSHIP OF SCIENTIFIC SOCIETIES

Académie nationale de pharmacie since 2017

OTHERS :

- Expert member of the "Commission d'Autorisation de Mise sur le Marché" (Agence Française de Sécurité Sanitaire-AFSSAPS) from april 1997 to 2012
- Member of the ANRS clinical trials scientific evaluation (AC5) since 2005 and coordinator of the pharmacology working group 1998-2017
- Member of the scientific advisory Board of the Clinical research department of Assistance Publique Hôpitaux de Paris from 2007-2013
- Member of Ethics Committee of Ile de France VII (located at Bicêtre Hospital) for more than 10 years, Vice president 2016-2018, President since 2018
- Member of Proposal Review Committee (PRC) at UNITAID since January 2014

PHARMACOLOGIST ADVISOR

Member of SAB of clinical studies: ANRS12374-3DICAmdolutegravir-based 3rd line treatment in Cambodia

Member of DSMB of COVID-19 french clinical trials (march 2020)

Advisor for favipiravir clinical trials (collaboration with UMR1137)

Advisor for INSERM/CEA/Paris-Sud University research unit (UMR1184): preclinical studies

SELECTED PUBLICATIONS (from > 150 publications as indexed in PubMed)

Atwine D, Baudin E, Gelé T, Muyindike W, Mworozzi K, Kyohairwe R, Kananura K, Orikiriza P, Nyehangane D, K T Nanjebe D, Furlan V, Verstuyft C, Barrail-Tran A, **Taburet AM**, Bonnet M; ANRS 12292 Rifavirenz study group . Effect of high-dose rifampicin on efavirenz pharmacokinetics: drug-drug interaction randomized trial. J Antimicrob Chemother. 2020;75:1250-1258

Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenue A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougere-Leurent C, Pageaux GP, Duclos-Vallée JC, **Taburet AM**, Coilly A. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Eur J Clin Pharmacol. 2019;75(11):1555-1563.

TH, Guedj J, Anglaret X, Laouénan C, Madelain V, **Taburet AM**, Baize S, Sissoko D, Pastorino B, Rodallec A, Piorkowski G, Carazo S, Conde MN, Gala JL, Bore JA, Carbonnelle C, Jacquot F, Raoul H, Malvy D, de Lamballerie X, Mentré F; JIKI study group. Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. PLoS Negl Trop Dis. 2017;11(2):e0005389.

Madelain V, Guedj J, Mentré F, Nguyen TH, Jacquot F, Oestereich L, Kadota T, Yamada K, **Taburet AM**, de Lamballerie X, Raoul H. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrob Agents Chemother. 2016;61(1).

Taburet AM, Sauvageon H, Grinsztejn B, Assuied A, Veloso V, Pilotto JH, De Castro N, Grondin C, Fagard C, Molina JM. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy. Clin Infect Dis. 2015;61(8):1328-35.

Bouazza N, Treluyer JM, Foissac F, Mentré F, **Taburet AM**, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P. Favipiravir for children with Ebola. *Lancet*. 2015;385(9968):603-4.
Mentré F, **Taburet AM**, Guedj J, Anglaret X, Keïta S, de Lamballerie X, Malvy D. Dose regimen of favipiravir for Ebola virus disease. *Lancet Infect Dis*. 2015;15(2):150-1.

Antonini TM, Furlan V, Teicher E, Haim-Boukobza S, Sebah M, Coilly A, Bonhomme-Faivre L, Roque-Afonso AM, Vittecoq D, Samuel D, **Taburet AM**, Duclos-Vallée JC. Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. *AIDS*. 2015;29(1):53-8.

Barau C, Braun J, Vincent C, Haim-Boukobza S, Molina JM, Mialhes P, Fournier I, Aboulker JP, Vittecoq D, Duclos-Vallée JC, **Taburet AM**, Teicher E; Agence Nationale de Recherche sur le Sida et les hépatites (ANRS) 148 Study Group. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the **LIVERAL-ANRS 148 study**. *Clin Infect Dis*. 2014;59(8):1177-84.

Bhatt NB, Baudin E, Meggi B, da Silva C, Barrail-Tran A, Furlan V, Grinsztejn B, Bonnet M, **Taburet AM**; **ANRS 12146/12214-CARINEMO Study Group**. Nevirapine or efavirenz for tuberculosis and HIV coinfecting patients: exposure and virological failure relationship. *J Antimicrob Chemother*. 2015 Jan;70(1):225-32.

Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, **Taburet AM**; **ANRS 12146-CARINEMO Study Group**. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfecting patients receiving nevirapine- or efavirenz-based antiretroviral treatment. *Antimicrob Agents Chemother*. 2014 Jun;58(6):3182-90.

Borand L, Madec Y, Laureillard D, Chou M, Marcy O, Pheng P, Prak N, Kim C, Lak KK, Hak C, Dim B, Nerrienet E, Fontanet A, Sok T, Goldfeld AE, Blanc FX, **Taburet AM**. Plasma concentrations, efficacy and safety of efavirenz in HIV-infected adults treated for tuberculosis in Cambodia (**ANRS 1295-CIPRA KH001CAMELIA trial**). *PLoS One*. 2014 Mar 7;9(3):e90350.

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, **Taburet AM**; **CAMELIA (ANRS 1295-CIPRA KH001) Study Group**. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. *J Infect Dis*. 2014;209(3):399-408.

Barrail-Tran A, Vincent C, Furlan V, Rosa I, Rosenthal E, Cheret A, Molina JM, **Taburet AM**, Piroth L; **ANRS HC30 QUADRIH Study Group**. Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. *Antimicrob Agents Chemother*. 2015;59(12):7903-5. doi: 10.1128/AAC.01603-15. Epub 2015 Oct 5.

Bouazza N, Treluyer JM, Foissac F, Mentré F, **Taburet AM**, Guedj J, Anglaret X, de Lamballerie X, Keïta S, Malvy D, Frange P. Favipiravir for children with Ebola. *Lancet*. 2015 Feb14;385(9968):603-4.

Bertrand J, Verstuyft C, Chou M, Borand L, Chea P, Nay KH, Blanc FX, Mentré F, **Taburet AM**; **CAMELIA (ANRS 1295-CIPRA KH001) Study Group**. Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. *J Infect Dis*. 2014;209(3):399-408.

March 28, 2020
Anne-Marie Taburet

